ERBB2 and breast carcinoma: Currently, the two approved techniques for HER2 status evaluation in breast cancer are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which detect HER2 protein overexpression and HER2 gene amplification (defined as an increased copy number of the chromosome 17 region [17q12q21]), respectively.